IMMUNO-ONCOLOGY INSIGHTS

Leveraging cutting edge tools to convert I-O data into knowledge

Guest Editor:
Jacques Moisan, Translational Innovation Platform - Immuno-Oncology Scientific Site Head (USA) at EMD Serono, Inc
Jacques Moisan
Translational Innovation Platform - Immuno-Oncology Scientific Site Head (USA) at EMD Serono, Inc

Yes, IMMUcan! Unraveling the human tumor microenvironment

H Hong,
Henoch Hong
at Merck KGaA
R Liechti,
Robin Liechti
at Swiss Institute of Bioinformatics
M Morfouace
Marie Morfouace
14 October 2021
Commentary

Expert Roundtable: leveraging cutting edge tools to convert...

A Sood,
Anil K Sood
Professor, Department of Gynecologic Oncology and Reproductive Medicine, UT MD Anderson Cancer Center
S Prabhakaran,
Sandhya Prabhakaran
Applied Research Scientist, Integrated Mathematical Oncology Department, Moffitt Cancer Centre
G Goldmacher et al.
Gregory Goldmacher
Executive Director, Clinical Research, Head of Clinical Imaging, Merck Research Laboratories
Greg has been at MSD since 2015. With his team of radiologists and imaging scientists, heoversees the clinical imaging in over 200 clinical trials in oncology and other therapeutic areas.He also leads research in radiomics, artificial intelligence, novel response criteria, tumorgrowth kinetics, and other innovative approaches to clinical trial imaging. Prior to MSD, hewas a senior medical director and head of oncology imaging at a global CRO, and before thatin academia. His clinical training was in diagnostic radiology, along with a PhD and postdoctoralwork in neuroscience, and business training in finance. In his ‘free’ time, he enjoysplaying with his kids, running, and training in the martial arts.
12 October 2021
Expert Roundtable

Expert Roundtable: leveraging cutting edge tools to convert...

A Sood,
Anil K Sood
Professor, Department of Gynecologic Oncology and Reproductive Medicine, UT MD Anderson Cancer Center
S Prabhakaran,
Sandhya Prabhakaran
Applied Research Scientist, Integrated Mathematical Oncology Department, Moffitt Cancer Centre
G Goldmacher et al.
Gregory Goldmacher
Executive Director, Clinical Research, Head of Clinical Imaging, Merck Research Laboratories
Greg has been at MSD since 2015. With his team of radiologists and imaging scientists, heoversees the clinical imaging in over 200 clinical trials in oncology and other therapeutic areas.He also leads research in radiomics, artificial intelligence, novel response criteria, tumorgrowth kinetics, and other innovative approaches to clinical trial imaging. Prior to MSD, hewas a senior medical director and head of oncology imaging at a global CRO, and before thatin academia. His clinical training was in diagnostic radiology, along with a PhD and postdoctoralwork in neuroscience, and business training in finance. In his ‘free’ time, he enjoysplaying with his kids, running, and training in the martial arts.
12 October 2021
Expert Roundtable Video

Cancer in 4D: the importance of spatial and temporal heterogeneity...

C Martinez
Constanza Martinez
Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada
11 October 2021
Commentary

Cell-based therapies for cancer treatment: leveraging advanced...

R Fan,
Rong Fan, PhD
Professor of Biomedical Engineering, Yale University
T Laskowski,
Tamara J Laskowski, PhD
Scientific Project Director, Adoptive Cell Therapy Platform, Dept. of Stem Cell Transplantation and Cellular Therapy MD Anderson Cancer Center
Dr. Tamara J. Laskowski received her doctorate degree in Human Molecular Genetics and Immunology from University of Texas Health Science Center where her work focused on genome editing of patient-derived stem cells to correct genetic mutations causative of Wiskott-Aldrich Syndrome, an immunodeficiency disorder that results in severe impairments to the immune system. Subsequently, Tamara joined Dr. Laurence J.N. Cooper’s laboratory at MD Anderson Cancer Center as a fellow. Her work focused on engineering stem cells with the goal of generating off-the-shelf NK and T-cell immunotherapies for targeting solid tumor malignancies. Though Tamara remains as a collaborator in the Cooper laboratory, her work has led her to transition to Dr. James Allison’s Immunotherapy Platform at MD Anderson. In her new role as Senior Research Scientist, Dr. Laskowski’s work primarily involves immune-monitoring of patients undergoing clinical trials in Immunotherapy and development of novel immunoassays. Dr. Laskowski also shares an interest in technology innovation, and has developed multi-plex assays for testing therapies against solid tumors. In 2017, this work led to an invitation to participate in the National Science Foundation (NSF) Innovation Corps, an exclusive program through which she was trained to develop strategies for expanding the economic and societal benefits of innovative ideas which have commercialization potential. She was the sole recipient of an award for outstanding performance upon completion of the program. In addition to her research work, Dr. Laskowski participates in several educational programs at MD Anderson. She is a lecturer at MD Anderson’s School of Health Professions and also serves as a scientific communications coach teaching students and fellows how to effectively communicate science and medicine with scientific and lay audiences.
N Senutovitch
Nina Senutovitch, PhD
Senior Scientist, Product Development, Cell Analytics, Sartorius
Dr. Nina Senutovitch received her BS in Biochemistry from New Mexico State University. She completed her PhD in Biological Sciences from Carnegie Mellon University, where she developed and detailed the function of novel fluorescent probes. As a post-doctoral fellow at the University of Pittsburgh, she established biosensor-based live cell screening assays for the detection of hepatotoxicity, including the use of a human liver “organ on a chip” model. She joined Sartorius in 2019 as a Senior Scientist in Cell Analytics
11 October 2021
Innovator Insight

The use of artificial intelligence in immuno-oncology drug...

C Boutton,
Carlo Boutton
Author for correspondence Large Molecules Research Sanofi, Technologiepark-21, B-9052 Zwijnaarde, Belgium carlo.boutton@sanofi.com
M Wendt
Maria Wendt
Large Molecules Research Sanofi, 49 New York Avenue, Framingham, MA 01701, USA
8 October 2021
Expert Insight
  • Enabling clinical grade manufacturing of gene-engineered NK cells

    N Moker,
    E Ullrich,
    R Rizwan
    Nina Moker
    Nina Moker
    R&D Scientist at Miltenyi Biotec
    Evelyn Ullrich
    Evelyn Ullrich
    Arbeitsgruppe Zelluläre Immunologie
    Romee Rizwan
    Romee Rizwan
    M.D at Harvard University
    30 Nov 2021
    38
    Days
    6
    Hrs
    30
    Min
    Register
  • Advancing engineered cell and gene therapy with precision gene editing

    J Harbottle,
    D Maddalo
    Jennifer Harbottle
    Jennifer Harbottle
    Senior Scientist, R&D, Cell and Gene Therapy at Horizon Discovery
    Danilo Maddalo
    Danilo Maddalo
    Group Leader, Translational Oncology at Genentech, Inc
    11 Nov 2021
    19
    Days
    6
    Hrs
    30
    Min
    Register
  • The therapeutic gene editing solution – cell therapy for solid tumors

    B Sasu,
    P Sivakumar,
    J Trager et al.
    Barbra Sasu
    Barbra Sasu
    Chief Scientific Officer at Allogene Therapeutics, Inc
    Pallavur Sivakumar
    Pallavur Sivakumar
    Scientific Vice President and Head of Discovery Immuno-Oncology and Cell Therapy Thematic Research Center at Bristol Myers Squibb
    James Trager
    James Trager
    Chief Scientific Officer at Nkarta Therapeutics, Inc
    Jennifer Harbottle
    Jennifer Harbottle
    Senior Scientist, R&D, Cell and Gene Therapy at Horizon Discovery
    30 September 2021
    Watch now
  • Gain deeper insights into the mechanisms of immune cell killing of tumor cells:...

    C Souders,
    T Dale,
    N Bevan et al.
    Colby Souders
    Colby Souders
    Chief Scientific Officer at Abveris
    Tim  Dale
    Tim Dale
    Head of BioAnalytics Applications at Sartorius
    Nicola Bevan
    Nicola Bevan
    Manager of Cell Imaging Applications at Sartorius
    Jeffrey Skolnik
    Jeffrey Skolnik
    Senior Vice President, Clinical Development at Inovio Pharmaceuticals, Inc
    6 October 2021
    Watch now
  • Get your non-viral T cell engineering process ready for clinical manufacturing

    M Rietenbach,
    S Wild,
    K Patel
    Melanie Rietenbach
    Melanie Rietenbach
    Global Product Manager at Miltenyi Biotec
    Stefan Wild
    Stefan Wild
    Senior Manager Research and Development at Miltenyi Biotec
    Kunal Patel
    Kunal Patel
    Process engineering manager at Miltenyi Biotec
    21 September 2021
    Watch now
  • Cell-based therapies for cancer treatment: leveraging advanced flow cytometry...

    N Senutovitch,
    R Fan,
    T Laskowski
    Nina Senutovitch
    Nina Senutovitch
    Senior Scientist, Cell Analytics Development at Sartorius
    Rong Fan
    Rong Fan
    Professor of Biomedical Engineering at Yale University
    Tamara Laskowski
    Tamara Laskowski
    Scientific Project Director at MD Anderson Cancer Center
    5 August 2021
    Watch now
  • Accelerating CAR-T process development: The power of process insight

    J Hupfeld
    Julia Hupfeld
    Julia Hupfeld
    Solution Marketing Manager at Sartorius
    29 July 2021
    Watch now
  • Applying a closed, modular, semi-automated system to CAR T cell therapy manufacturing

    Y Ji,
    S Ensari, PhD,
    N Moore
    Yongchang Ji
    Yongchang Ji
    Scientist II, Cell Transfection Group at Thermo Fisher Scientific
    Semsi Ensari, PhD
    Semsi Ensari, PhD
    Senior Director at Kite Pharma, Inc
    Nathan Moore
    Nathan Moore
    Associate Director, Engineering & Automation Cell Therapies, Pharmaceutical Sciences at Takeda Pharmaceutical Company Limited
    29 June 2021
    Watch now
  • Latest content

    The therapeutic gene editing solution – cell therapy for solid tumors

    B Sasu,
    P Sivakumar,
    J Trager et al.
    Barbra Sasu, PhD
    Barbra Sasu, PhD
    Chief Scientific Officer, Allogene Therapeutics
    Pallavur Sivakumar, PhD
    Pallavur Sivakumar, PhD
    Scientific Vice President and Head of Discovery, Immuno-Oncology and Cell Therapy Thematic Research Center, Bristol Myers Squibb
    James Trager, PhD
    James Trager, PhD
    Chief Scientific Officer, Nkarta Therapeutics
    Jennifer Harbottle, PhD
    Jennifer Harbottle, PhD
    Senior Scientist, R&D, Cell and Gene Therapy, Horizon Discovery
    30 September 2021
    Watch now